# Vocabria (cabotegravir sodium) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/cabotegravir

> The FDA approved Vocabria (cabotegravir sodium), sponsored by GSK plc (GSK), on December 20, 2021.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Vocabria (cabotegravir sodium) |
| Codes |  |
| Sponsor | GSK plc (GSK) https://sec-api.dev/companies/gsk/catalysts |
| Indications | [HIV Infections](https://sec-api.dev/indications/hiv-infections) |
| Modality |  |
| FDA designations | priority review |

## Timeline

### December 19, 2019: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA complete response letter database: "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." https://api.fda.gov/transparency/crl.json?search=file_name:%22212887Orig1s000%2C212888Orig1s000OtherActionLtrs.pdf%22

### January 21, 2021: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA212887 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20210121, review_priority PRIORITY; sponsor_name VIIV HLTHCARE; product VOCABRIA (CABOTEGRAVIR SODIUM)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212887%22

### December 20, 2021: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA215499 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20211220, review_priority PRIORITY; sponsor_name VIIV HLTHCARE; product APRETUDE (CABOTEGRAVIR)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215499%22

### December 20, 2021: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA212887 SUPPL-4 (Efficacy): submission_status AP, submission_status_date 20211220, review_priority PRIORITY; sponsor_name VIIV HLTHCARE; product VOCABRIA (CABOTEGRAVIR SODIUM)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212887%22

### January 31, 2022: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA212887 SUPPL-1 (Efficacy): submission_status AP, submission_status_date 20220131, review_priority STANDARD; sponsor_name VIIV HLTHCARE; product VOCABRIA (CABOTEGRAVIR SODIUM)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212887%22
- openFDA Drugs@FDA: "NDA212887 SUPPL-2 (Efficacy): submission_status AP, submission_status_date 20220207, review_priority STANDARD; sponsor_name VIIV HLTHCARE; product VOCABRIA (CABOTEGRAVIR SODIUM)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212887%22

### March 23, 2022: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA212887 SUPPL-3 (Efficacy): submission_status AP, submission_status_date 20220323, review_priority STANDARD; sponsor_name VIIV HLTHCARE; product VOCABRIA (CABOTEGRAVIR SODIUM)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212887%22
- openFDA Drugs@FDA: "NDA212887 SUPPL-6 (Efficacy): submission_status AP, submission_status_date 20220329, review_priority PRIORITY; sponsor_name VIIV HLTHCARE; product VOCABRIA (CABOTEGRAVIR SODIUM)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212887%22
- openFDA Drugs@FDA: "NDA212887 SUPPL-5 (Efficacy): submission_status AP, submission_status_date 20220329, review_priority PRIORITY; sponsor_name VIIV HLTHCARE; product VOCABRIA (CABOTEGRAVIR SODIUM)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212887%22

### September 20, 2024: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA212887 SUPPL-9 (Efficacy): submission_status AP, submission_status_date 20240920, review_priority PRIORITY; sponsor_name VIIV HLTHCARE; product VOCABRIA (CABOTEGRAVIR SODIUM)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212887%22
- openFDA Drugs@FDA: "NDA212887 SUPPL-10 (Efficacy): submission_status AP, submission_status_date 20240920, review_priority STANDARD; sponsor_name VIIV HLTHCARE; product VOCABRIA (CABOTEGRAVIR SODIUM)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212887%22
- openFDA Drugs@FDA: "NDA215499 SUPPL-8 (Efficacy): submission_status AP, submission_status_date 20240920, review_priority STANDARD; sponsor_name VIIV HLTHCARE; product APRETUDE (CABOTEGRAVIR)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215499%22

### May 27, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: HIV Infections.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05996471 (A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-05-27 (ACTUAL); Lead Sponsor ViiV Healthcare." https://clinicaltrials.gov/study/NCT05996471

## Same indication

- [Cab la](https://sec-api.dev/pdufa/cab-la) (GSK)
- [Cab la + rpv la](https://sec-api.dev/pdufa/cab-la-rpv-la) (GSK)
- [Dtg/3tc](https://sec-api.dev/pdufa/dtg-3tc) (GSK)
- [Yeztugo® (lenacapavir)](https://sec-api.dev/pdufa/lenacapavir) (GILD)
- [VH4524184](https://sec-api.dev/pdufa/vh4524184) (GSK)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/cabotegravir.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Vocabria (cabotegravir sodium) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/cabotegravir

```bibtex
@misc{secapidev_pdufa_cabotegravir_20261116,
  title        = {Vocabria (cabotegravir sodium) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/cabotegravir}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_cabotegravir_20261116","title":"Vocabria (cabotegravir sodium) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/cabotegravir","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
